Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.

Feb 2 (Reuters) - Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Pfizer (PFE) stock dips as the company projects a revenue decline for 2026 amid a nearly $1.5B impact attributed to patent ...

Pharmaceutical giant Pfizer (PFE) released its fourth quarter earnings results that topped Wall Street's expectations on its ...

Pfizer (PFE) stock falls as the company posts mid-stage trial data for obesity therapy PF’3944. Read more here.

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets ...

NEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Tuesday reported a loss of $1.65 billion in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 29 cents.

Pharmaceutical company’s stock price move diverges from rival Merck as both groups bolster new treatment pipelines ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...